AXSM
Axsome Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$221.64-3.63%
Price as of Jul 20, 2026
AXSM financials
Axsome Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $638.5M | $385.7M | $270.6M | $50.0M |
| Cost of revenue | $47.5M | $33.3M | $26.1M | $5.2M |
| Gross profit | $591.0M | $352.4M | $244.5M | $44.8M |
| Operating expenses | $760.3M | $633.0M | $476.4M | $224.6M |
| Operating income | -$169.2M | -$280.6M | -$231.8M | -$179.8M |
| Net income | -$183.2M | -$287.2M | -$239.2M | -$187.1M |
| EBITDA | -$168.1M | -$272.6M | -$225.0M | -$175.4M |
| Basic EPS | $-3.68 | $-5.99 | $-5.27 | $-4.60 |
| Diluted EPS | $-3.68 | $-5.99 | $-5.27 | $-4.60 |
| Balance sheet | ||||
| Cash & equivalents | $322.9M | $315.4M | $386.2M | $200.8M |
| Total assets | $689.8M | $568.5M | $588.2M | $331.5M |
| Total liabilities | $601.5M | $511.5M | $397.3M | $221.9M |
| Stockholders’ equity | $88.3M | $57.0M | $191.0M | $109.6M |
| Total debt | $241.3M | $193.0M | $186.4M | $94.7M |
| Net debt | -$81.6M | -$122.4M | -$199.8M | -$106.2M |
| Cash flow | ||||
| Operating cash flow | -$93.4M | -$128.4M | -$145.1M | -$116.5M |
| Capital expenditure | -$480.0K | -$270.0K | -$582.0K | -$702.0K |
| Free cash flow | -$93.9M | -$128.7M | -$145.7M | -$117.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |